Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other ITP symptoms ITP is a rare disease of complex immune dysregulation leading to ...

Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...

PARIS - The European Commission has approved Sanofi’s Wayrilz (rilzabrutinib) as the first Bruton’s tyrosine kinase (BTK) inhibitor for treating immune thrombocytopenia (ITP) in adult patients who are ...

Frontline setting accelerates potential for deep, durable responses in the treatment of liver cancers Study builds on clinical validation from one of the largest datasets in the in vivo CAR field ...

Powered by advanced factor research and daily refreshed data, Bloomberg’s MAC3 Risk Model transforms how investors see and manage risk in a multi-asset world. Bloomberg MAC3 gives investors a unified ...

KUTV — For nearly 30 years, 4Life has led the way in immune system innovation, developing science-backed nutraceuticals that help the body recognize, remember, and respond to immune challenges. Kari ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...

Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in bleeding, quality of life measures, and other ITP symptoms If approved, ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for rilzabrutinib (Wayrilz, Sanofi) to treat immune thrombocytopenia (ITP) in adults who are refractory to other ...

Background: Mitophagy receptor-related genes (MRRGs) orchestrate mitochondrial quality control and may shape glioma progression and immune tolerance, yet their integrated prognostic and ...

CREATE Medicines ("CREATE") broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, ...